A case of relapsing secondary bladder adenocarcinoma after right colonic cancer.
BACKGROUND
A 71-year-old woman was referred to a surgical oncology clinic after CT raised suspicion for a bladder neoplasm. She had previously undergone right hemicolectomy and received adjuvant chemotherapy for pT3N1MX cancer of the cecum. A retroperitoneal recurrence had been deemed unsuitable for surgical resection, and had instead been treated with chemoradiation therapy. Follow-up CT raised suspicion for a possible bladder neoplasm.


METHODS
CT, physical examination, urinalysis, cystoscopy with biopsy, pathological analysis and immunohistochemical analysis.


METHODS
Adenocarcinoma of the cecum metastatic to the bladder.


RESULTS
The patient underwent open bladder resection with total excision of the neoplasm and was administered adjuvant chemotherapy consisting of irinotecan and cetuximab. Subsequent recurrences at the same site were treated with transurethral resection, while chemotherapy was still in progress. At 7 months' follow-up, the patient remained alive, with no evidence of further recurrence.
Izzo
Luciano
L
La Sapienza University, Rome, Italy. luciano.izzo@uniroma1.it
Pietrasanta
Dario
D
Izzo
Paolo
P
Caputo
Maria
M
Di Cello
Pierfrancesco
P
Meloni
Paolo
P
Bolognese
Antonio
A
D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology* / Q000601:surgery; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D002430:Cecal Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology* / Q000601:surgery; D000068818:Cetuximab; D017024:Chemotherapy, Adjuvant; D003082:Colectomy; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D007150:Immunohistochemistry; D000077146:Irinotecan; D002955:Leucovorin / Q000627:therapeutic use; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D012186:Retroperitoneal Neoplasms / Q000473:pathology / Q000556:secondary; D012447:Sacrum / Q000473:pathology; D013876:Thiophenes / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed; D001749:Urinary Bladder Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000378:metabolism / Q000556:secondary* / Q000601:surgery
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000964:Antimetabolites, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D009944:Organoplatinum Compounds; D011799:Quinazolines; D013876:Thiophenes; D000077146:Irinotecan; C068874:raltitrexed; D000068818:Cetuximab; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin